Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4506 On Other Exchanges
Symbol
Exchange
4506 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and other regions. The company offers pharmaceutical products, such as therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; antidepressants; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for therapeutic indications, such as Anderson-Fabry disease, anti-hypertension, gastroprokines, carbapenem antibiotics, sedative hypnotics, short-acting and long-acting beta-agonist, inhaled corticosteroid, corticosteroid nasal spray, and serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, seasonings, and sweeteners; and chemical product materials, such as cosmetic and coating materials, active pharmaceutical ingredients, and electronic chemicals. Further, it offers veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases and acute myocardial infarctions; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI608 and BBI503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. operates as a subsidiary of Sumitomo Chemical Co. Ltd.

6,868 Employees
Last Reported Date: 06/19/15
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Sumitomo Dainippon Pharma Co., Ltd. Provides Interim and Year End Dividend Guidance for the Year Ending March 31, 2016

Sumitomo Dainippon Pharma Co., Ltd. provided interim and year end dividend guidance for the year ending March 31, 2016. For the first half of year ending March 31, 2016, the company expects dividend of JPY 9 per share compared to JPY 9 per share a year ago. For the full year ending March 31, 2016, the company expects year end dividend of JPY 9 per share and annual dividend of JPY 18 per share compared to year end dividend of JPY 9 per share and annual dividend of JPY 18 per share a year ago.

Sumitomo Dainippon Pharma Co., Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Revises Earnings Guidance for the Six Months Ending September 30, 2015 and Year Ending March 31, 2016

Sumitomo Dainippon Pharma Co., Ltd. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net income attributable to owners of the parent of JPY 5.9 billion compared to JPY 5.8 billion a year ago. Net sales were JPY 98.1 billion compared to JPY 89.7 billion a year ago. Operating income was JPY 4.4 billion compared to JPY 8.7 billion a year ago. Ordinary income was JPY 4.7 billion compared to JPY 9.6 billion a year ago. EBITDA was JPY 9.7 billion compared to JPY 14.9 billion a year ago. Earnings per share was JPY 14.95 against JPY 14.49 a year ago. Income before income taxes was JPY 10,576 million against JPY 11,134 million a year ago. Capital expenditures were JPY 1.0 billion against JPY 1.9 billion a year ago. Net cash provided by operating activities was JPY 5.4 billion against JPY 8.8 billion a year ago. Return on equity was 1.3% against 1.4% a year ago. The sales increased by JPY 8.4 billion from the same period last year. The increase was driven primarily by North America segment. Decrease in income was due to the increase in advertising and marketing expenses in North America as well as the increase in R&D costs. For the six months ending September 30, 2015, the company expects the yen to be weaker than in the May forecast, and revise the forecasted net sales upward by JPY 4.5 billion to JPY 197.5 billion against previous forecast of JPY 193.0 billion. The company expects unchanged May forecast of operating income of JPY 11,000 million, ordinary income of JPY 11,000 million and net income attributable to owners of the parent of JPY 8,000 million or JPY 20.14 per share. EBITDA is expected to be JPY 21.7 billion against prior guidance of JPY 21.5 billion. The company expects return on equity of 1.8%. For the year ending March 31, 2016, the company expects net sales of JPY 401.0 billion against prior guidance of JPY 392.0 billion. The company expects operating income of JPY 27,000 million, ordinary income of JPY 26,500 million and net income attributable to owners of the parent of JPY 18,000 million or JPY 45.31 per share. EBITDA is expected to be JPY 47.8 billion against prior guidance of JPY 47.5 billion. The company expects return on equity of 3.9% and capital expenditures of JPY 11.5 billion, depreciation and amortization of property, plant and equipment of JPY 7.4 billion, depreciation and amortization of intangible assets of JPY 5.1 billion and depreciation and amortization of goodwill of JPY 6.5 billion. The company revised financial forecast due to the weakening of the yen, although the progress in each country in the local currency is on track.

Sumitomo Dainippon Pharma Co., Ltd., Q1 2016 Earnings Call, Jul 29, 2015

Sumitomo Dainippon Pharma Co., Ltd., Q1 2016 Earnings Call, Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,310.00 JPY +60.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $19.60 USD -0.34
Eastman Kodak Co $13.59 USD -0.49
FUJIFILM Holdings Corp ¥4,766 JPY -11.00
GlaxoSmithKline Consumer Nigeria PLC 35.00 NGN 0.00
Pernix Therapeutics Holdings Inc $4.69 USD -0.13
View Industry Companies
 

Industry Analysis

4506

Industry Average

Valuation 4506 Industry Range
Price/Earnings 32.1x
Price/Sales 1.3x
Price/Book 1.1x
Price/Cash Flow 24.2x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMITOMO DAINIPPON PHARMA CO, please visit www.ds-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.